Genes in panel
STRs in panel
Prev Next
Regions in panel
Prev Next

BabyScreen+ newborn screening

Gene: NPC1

Green List (high evidence)

NPC1 (NPC intracellular cholesterol transporter 1)
EnsemblGeneIds (GRCh38): ENSG00000141458
EnsemblGeneIds (GRCh37): ENSG00000141458
OMIM: 607623, Gene2Phenotype
NPC1 is in 21 panels

3 reviews

John Christodoulou (Murdoch Children's Research Institute)

Green List (high evidence)

Gene-disease association: strong. Niemann-Pick typeC


Severity: variable, but is often severe


Age of onset: infantile - adulthood; most commonly in early childhood


Non-molecular confirmatory testing: yes, oxysterol measurement;


Treatment: miglustat, intrathecal cyclodextrin
Created: 1 Nov 2022, 5:21 a.m. | Last Modified: 1 Nov 2022, 5:21 a.m.
Panel Version: 0.719

Mode of inheritance
BIALLELIC, autosomal or pseudoautosomal

Phenotypes
hepatosplenomegaly; cholestatic jaundice; gaze palsy; ID; dystonia; dementia

Publications

Zornitza Stark (Victorian Clinical Genetics Services; Australian Genomics)

Green List (high evidence)

For review: check treatment available locally. Done.
Created: 6 Oct 2022, 2:53 a.m. | Last Modified: 2 Nov 2022, 6:05 a.m.
Panel Version: 0.721

Mode of inheritance
BIALLELIC, autosomal or pseudoautosomal

Phenotypes
Niemann-Pick disease, MIM# 257220

David Amor (Murdoch Children's Research Institute)

Green List (high evidence)

Gene-disease association: strong. Niemann-Pick disease type C (NPC) is a slowly progressive lysosomal disorder whose principal manifestations are age dependent. The manifestations in the perinatal period and infancy are predominantly visceral, with hepatosplenomegaly, jaundice, and (in some instances) pulmonary infiltrates. From late infancy onward, the presentation is dominated by neurologic manifestations.

Severity: severe

Age of onset: infant

Non-molecular confirmatory testing: yes, oxysterol analysis

Treatment: Treatment with miglustat, approved for the management of neurologic manifestations of NPC in several countries but not the United States, has increased survival by five years from date of diagnosis or approximately ten years from onset of neurologic manifestations. I am making green for this reason, but may be questionable.
Created: 5 Oct 2022, 1:03 a.m. | Last Modified: 5 Oct 2022, 1:03 a.m.
Panel Version: 0.274

Mode of inheritance
BIALLELIC, autosomal or pseudoautosomal

Phenotypes
Niemann-Pick disease, type C, NPC1

Publications

History Filter Activity

29 Dec 2022, Gel status: 3

Added Tag, Added Tag

Zornitza Stark (Victorian Clinical Genetics Services; Australian Genomics)

Tag treatable tag was added to gene: NPC1. Tag metabolic tag was added to gene: NPC1.

2 Nov 2022, Gel status: 3

Removed Tag

Zornitza Stark (Victorian Clinical Genetics Services; Australian Genomics)

Tag for review was removed from gene: NPC1.

6 Oct 2022, Gel status: 3

Entity classified by Genomics England curator

Zornitza Stark (Victorian Clinical Genetics Services; Australian Genomics)

Gene: npc1 has been classified as Green List (High Evidence).

6 Oct 2022, Gel status: 3

Set publications

Zornitza Stark (Victorian Clinical Genetics Services; Australian Genomics)

Publications for gene: NPC1 were set to

6 Oct 2022, Gel status: 3

Added Tag

Zornitza Stark (Victorian Clinical Genetics Services; Australian Genomics)

Tag for review tag was added to gene: NPC1.

18 Sep 2022, Gel status: 3

Created, Added New Source, Set mode of inheritance, Set Phenotypes

Zornitza Stark (Victorian Clinical Genetics Services; Australian Genomics)

gene: NPC1 was added gene: NPC1 was added to gNBS. Sources: BeginNGS,BabySeq Category A gene,Expert Review Green Mode of inheritance for gene: NPC1 was set to BIALLELIC, autosomal or pseudoautosomal Phenotypes for gene: NPC1 were set to Niemann-Pick disease type C1, MIM#257220